Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.

Andreas SeeberLukas WeissFranz RomederJoanna SzkanderaThomas KuehrSusanne KostnerPetra PichlerThomas JaegerFlorian KocherRichard GreilThomas Brodowicz

Published in: Wiener klinische Wochenschrift (2019)

In this real-world analysis the outcome was less pronounced compared to the results of both the phase Ib/II approval trial and the confirmatory phase III trial. The latter failed to show an improvement in OS and PFS for the doxorubicin/olaratumab combination. As such, olaratumab should not be used anymore in patients with STS.

Keyphrases

phase iii
open label
clinical trial
phase ii
double blind
placebo controlled
squamous cell carcinoma
small cell lung cancer
drug delivery
study protocol
randomized controlled trial
electronic health record
cancer therapy
machine learning
deep learning